Strattera: Instructions for use of the drug

Strattera is prescribed to treat attention deficit hyperactivity disorder. Active substance:

Atomoxetine.

Pharmacological group of Strattera

Adrenergic and sympathomimetic (alpha, beta)

The nosological classification (ICD-10) of Strattera

F90.0 Violation of activity and attention

Additional ingredients: dimethicone, pregelatinized starch

Capsule shell composition: titanium dioxide, sodium lauryl sulfate, gelatin

Before using the medication please consult with your doctor to avoid overdose Strattera and not cause a complication of the disease. Take it once or twice daily with or without food. Take the capsules whole, do not crush them and sprinkle on food. If Strattera should be canceled, it does not require a gradual reduction of the dose.

Before using the medication please consult with your doctor to avoid overdose Strattera and not cause a complication of the disease. Take it once or twice daily with or without food. Take the capsules whole, do not crush them and sprinkle on food. If Strattera should be canceled, it does not require a gradual reduction of the dose.

The drug forms of Strattera

Capsules 10 mg — Hard gelatin, size â„–3, opaque, white / white, with applied dosage «10 mg» and the identification code «Lilly 3227″.

Capsules 18 mg — Hard gelatin, size â„–3, opaque, yellow / white, with applied dosage «18 mg» and the identification code «Lilly 3238″.

Capsules 25 mg — Hard gelatin, size â„–3, opaque blue / white, with applied dosage «25 mg» and the identification code «Lilly 3228″.

Capsules 40 mg — Hard gelatin, size â„–3, opaque, blue / blue, with applied dosage «40 mg» and the identification code «Lilly 3229″.

Capsules 60 mg — Hard gelatin, size â„–2, opaque, blue / yellow, with applied dosage «60 mg» and the identification code «Lilly 3239″.

The contents of capsules — a powder, from white to almost white.

Indications for use Strattera

Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents and adults.

Contraindications of Strattera

Hypersensitivity to the drug;

severe heart disease;

concurrent use with MAO inhibitors;

angle-closure glaucoma.

With caution in patients with hypertension, tachycardia, cardiovascular diseases, severe physical congestion, while taking psychostimulants, sudden cardiac death in the family history, cerebrovascular, convulsive seizures in history, as well as for conditions that can lead to hypotension .

Side effects of Strattera

Children and adolescents

From the digestive system: very common (> 10%) — abdominal pain (18%, including the effects of abdominal discomfort, pain, and epigastric discomfort, discomfort in the stomach), decreased appetite (16%), vomiting (11%) ; often (1-10%) — constipation, dyspepsia, nausea (9%), anorexia.

Nausea (9%) and vomiting (11%) are most likely to occur during the first month of treatment, usually mild to moderate severity, are temporary and do not cause discontinuation of treatment in a significant number of cases.

Cardio-vascular system: (0.1-1%) — palpitations, sinus tachycardia.

In placebo-controlled trials in children treated with Strattera, noted an average increase in heart rate of 6 beats / min, and the average increase Sad Dad — 2 mm Hg compared to placebo.

Patients treated with atomoxetine, orthostatic hypotension observed (0,2%, n = 7) and syncope (0,8%, n = 26), due to its effect on noradrenergic tone.

CNS: very common (> 10%) — somnolence (including sedation); often (1-10%) — irritability, mood swings, dizziness; sometimes (0.1-1%) — early morning awakening.

On the part of the organ of vision: common (1-10%) — mydriasis.

Dermatological reactions: often (1-10%) — dermatitis, rash; sometimes (0.1-1%) — itching.

Other: often (1-10%) — flu, fatigue, weight loss; sometimes (0.1-1%) — weakness.

Side effects in patients with slow metabolism: tremor (5.1 and 1.1%, respectively), syncope (2.1 and 0.7%, respectively), conjunctivitis (3 and 1.5% respectively), early morning awakening (3 and 1.1%, respectively), mydriasis (2.5 and 0.7% respectively).

Adults

From the digestive system: very common (> 10%) — decreased appetite, dry mouth, nausea; often (1-10%) — abdominal pain (including effects of abdominal discomfort, pain, and epigastric discomfort, discomfort in the stomach), constipation, dyspepsia, flatulence.

CNS: very common (> 10%) — insomnia (difficulty falling asleep and include sleep disturbance at night); often (1-10%) — decreased libido, dizziness, sleep quality, sinus headache; sometimes (0.1-1%) — early morning awakening.

Since the cardiovascular system: often (1-10%) — flushing, palpitations, tachycardia; sometimes (0.1-1%) — the feeling of cold in the lower limbs; very rare (<0.01%) according to the spontaneous (postmarketing reports) — peripheral vascular reactions and / or Raynaud’s syndrome, Raynaud’s syndrome, the risk of recurrence.

From the urinary system: often (1-10%) — dysuria, difficulty urinating.

From the reproductive system: often (1-10%) — dysmenorrhea, abnormal ejaculation, lack of ejaculation, erectile dysfunction, erectile dysfunction, menstrual disorders, violation of orgasm; very rare (<0.01%), according to the spontaneous (postmarketing) reports — a painful or prolonged erection.

Skin and subcutaneous tissue: common (1-10%) — dermatitis, increased sweating.

Other: often (1-10%) — weakness, drowsiness, chills, weight loss.